Volta Medical

• 06/01/2023
• Series B
• $37,900,000

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures.

Volta’s DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters.

The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation.

VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space.

Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

---

---